Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. - Wikidata - wikimedia - TriplyDB

Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study.

Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study.

http://www.wikidata.org/entity/Q33869831

about

Antidepressants for agitation and psychosis in dementia Potential drug-drug interactions in Alzheimer patients with behavioral symptoms Use of atypical antipsychotics in the elderly: a clinical review Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend Analysis The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease Modern antipsychotic drugs: a critical overview Trends in use of antipsychotics in elderly patients with dementia: Impact of national safety warnings Performance of a semi-automated approach for risk estimation using a common data model for longitudinal healthcare databases.Instrumental variable applications using nursing home prescribing preferences in comparative effectiveness research Quantifying the role of adverse events in the mortality difference between first and second-generation antipsychotics in older adults: systematic review and meta-synthesis.Clinical pharmacology and vascular risk.A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data Treatment advances in Alzheimer's disease based on the oxidative stress model.Choice of observational study design impacts on measurement of antipsychotic risks in the elderly: a systematic review.The explanatory role of stroke as a mediator of the mortality risk difference between older adults who initiate first- versus second-generation antipsychotic drugs Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review.Safety and efficacy of antipsychotic drugs for the behavioral and psychological symptoms of dementia.Approach to managing behavioural disturbances in dementia.Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics Cardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort study.Risk of ischemic stroke associated with the use of antipsychotic drugs in elderly patients: a retrospective cohort study in Korea.Antipsychotic drugs and risks of myocardial infarction: a self-controlled case series study Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: A randomized controlled trial.Quetiapine safety in older adults: a systematic literature review.Association of Selected Antipsychotic Agents With Major Adverse Cardiovascular Events and Noncardiovascular Mortality in Elderly Persons.Effect of different antipsychotic drugs on short-term mortality in stroke patients.Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.Initiation of benzodiazepines in the elderly after hospitalization.Practical application of nonrandomized research to patient care: a case study of nesiritide.Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.Exposure to antipsychotics and risk of stroke: self controlled case series study ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia.Novel uses for risperidone: focus on depressive, anxiety and behavioral disorders.Off-label use of antipsychotics: are we mad?Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease.Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease.Beyond the Black Box: What is The Role for Antipsychotics in Dementia?Atypical antipsychotics to treat the neuropsychiatric symptoms of dementia.Improving physical health monitoring for patients with chronic mental health problems who receive antipsychotic medications.Antipsychotics for the treatment of behavioral and psychological symptoms of dementia (BPSD)

P2860

Q24241426-F3229FAF-AF0F-4FD3-B776-A147E7CEDFC9 Q26782490-4C0D3087-29AC-41F6-BD73-00869F0B9D29 Q26827756-436D9683-6606-4460-97C9-C583C3F4D8BB Q28551085-3B68CBF0-4552-4B25-AF6D-3A5565CC657D Q30413790-2974B6EC-D0E8-4BFC-9BFA-DAB3BC0BED98 Q33853390-58052202-3A10-4318-8328-7935E2E2FF9A Q33888723-C4D13875-1300-48D9-8595-2621E1937B5E Q33934896-57CDED49-C268-4E35-AF2F-302A14E9A28B Q33976565-92E7F0D9-FC69-4104-8E73-89A3A2721E44 Q34070862-93EBCDE9-EA39-4DB5-8158-2A812FD258E9 Q34072168-8129BA6A-BE64-469A-AA0E-A56474ED44FB Q34133867-4F0BE25C-13F4-4CEE-A3C4-C09CE0AE2799 Q34167375-DC083C6F-D014-4DAC-B23A-A5DEBA76049B Q34298335-E3542B4B-E20A-45ED-876F-9DBE04D2B5CC Q34300560-AF5CC9CA-96A1-4673-A858-7A0AB0475DAC Q34452896-2030C71E-3027-4F9D-BBEE-C95406972721 Q34571959-ED600EA8-3BE7-49A3-8D37-BF309969B327 Q34683770-09BB1858-6861-484E-99CF-945099A62B95 Q34965949-1236C283-E2CA-4DD5-8936-009391779473 Q35087495-1E3CA719-D4B6-47CF-B4F5-193E26B916FF Q35196617-DBC83398-0FFB-4BAA-851F-C9CD69ABE369 Q35502460-F4B33AC1-C6FF-491B-972E-FECA865A0C00 Q35730949-636F28A7-6B3C-41A4-84E9-F934CD25BBBE Q35905294-E9097C2B-4696-47D0-A7C4-67D68346758A Q36141743-BF883EFF-C6CF-4557-A393-A84A94D906A8 Q36193754-082890C6-BC61-4B11-B5DE-A1617F1349FF Q36513610-2BC01EB9-9A00-4CBB-AE8F-9F5A82538CDD Q36580458-BE78D751-8D82-4391-9207-250F2DA99754 Q36693881-DDCAC784-8B1D-40B9-948F-99CA8C2C14F8 Q36742405-A2CE38E9-0ABD-41A7-B610-78332B0A6262 Q36854680-A339DA65-B933-4579-896D-3976E01852E9 Q36885358-175FE010-1FE7-4DBB-BABB-1BAAD3F54453 Q36904901-4F3D4F09-58F7-4F97-96FC-6A53875AD3E0 Q36945015-55493830-CE6D-41AC-91E5-F69F123E98EF Q36978027-BE3B5C58-3618-4718-B3E8-804DED1460DF Q37004363-DD89F6F5-45E9-4E61-A579-B94CE467A4E7 Q37094302-39CC0FD1-A586-4D85-BE9A-C8B5B465179E Q37166113-623B0503-1E19-4F1D-8A58-508B94113805 Q37195748-B38D1EE2-8BCE-40BE-A370-84BA3629D26C Q37420475-C94F76EF-BCEE-4EAC-BD69-660E975A0F5A

P2860

Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study.

http://www.wikidata.org/entity/Q33869831

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Atypical antipsychotic drugs a ...... ed retrospective cohort study.

@ast

Atypical antipsychotic drugs a ...... ed retrospective cohort study.

@en

type

label

Atypical antipsychotic drugs a ...... ed retrospective cohort study.

@ast

Atypical antipsychotic drugs a ...... ed retrospective cohort study.

@en

prefLabel

Atypical antipsychotic drugs a ...... ed retrospective cohort study.

@ast

Atypical antipsychotic drugs a ...... ed retrospective cohort study.

@en

P1433

Q33869831-8318A82B-6464-4C30-8002-445B912662BF

P1476

Q33869831-113EEBF9-555E-4CF2-A355-D13EF3139228

P2093

Q33869831-0825330F-713E-43F7-A361-487808BE0B9C

Q33869831-0926EB48-6983-431D-A32B-8AD15781BCAD

Q33869831-2B3A8942-2711-45C7-B032-026AFF31566A

Q33869831-5FC7440F-ADB4-410B-8FA4-EAB429EDBCB7

Q33869831-6BCE9505-D69B-457E-ABE3-3925EADFDB7A

Q33869831-7B73970C-819A-4856-B492-D5E60A588380

Q33869831-80E564D2-1C69-4924-B943-1FCFCECE95B2

Q33869831-A484918C-C6CD-4CDC-B0FF-F1438C3A502F

Q33869831-D1838953-AF16-4A4E-A80B-2B552D5F1B0A

Q33869831-EE6D6F4C-C9BE-4CCD-9B8F-E510F1C51E46

P2860

Q33869831-17F6DE86-0AD0-4925-B059-58BC48D1F6F3

Q33869831-2E304F6B-5DF8-413A-95C0-54632CDA8CB0

Q33869831-3354F0E6-5353-41F9-9528-C3ADFFC4586C

Q33869831-3B9414CB-0CF1-4745-B323-F13591BC90DC

Q33869831-44345914-3DC4-41B6-A198-6F40D0B0D044

Q33869831-47BC19B1-029B-47C4-99E0-762FA8C9AA1C

Q33869831-4D8F9FBB-0BEF-49CE-885F-458EB3555438

Q33869831-5091EC2B-36F4-4846-B6CC-EFE5A46E53D5

Q33869831-52D60263-3A4D-47B3-B323-9DAEEC20E3DC

Q33869831-535F72BA-DB5C-4EB6-88D2-A33FFED82298

P304

Q33869831-625732CF-7AE6-4668-A0C8-C8AC8D5BB24F

P31

Q33869831-7E61669F-FA7B-4D90-90EF-841406088036

P356

Q33869831-8E76A9E2-66C1-4217-85B3-BD3CDE7E11C5

P407

Q33869831-A92C22EF-03C9-4FA2-99DF-CF9412DB0579

P433

Q33869831-06053F40-3A1C-4CB3-9DA6-3A0BA1339D5D

P478

Q33869831-D3AC0C7D-FF3A-4CC4-8FEC-0B876FB2C6C5

P50

Q33869831-8B0FBC56-B07A-4D7E-B99D-D079DE0A758F

P577

Q33869831-F66F3040-5EA0-4CB3-9B5E-2E487D15FC0D

P698

Q33869831-9E3CBF6D-99F2-40E7-8B49-2D2E03DAED12

P932

Q33869831-511537FC-E900-4762-9D34-DFD1631173FC

P356

BMJ.38330.470486.8F

P1433

P1476

Atypical antipsychotic drugs a ...... ed retrospective cohort study.

@en

P2093

Jerry H Gurwitz

http://www.w3.org/2001/XMLSchema#string

Kathy Sykora

http://www.w3.org/2001/XMLSchema#string

Muhammad Mamdani

http://www.w3.org/2001/XMLSchema#string

Nadia Gunraj

http://www.w3.org/2001/XMLSchema#string

Nathan Herrmann

http://www.w3.org/2001/XMLSchema#string

Paula A Rochon

http://www.w3.org/2001/XMLSchema#string

Philip E Lee

http://www.w3.org/2001/XMLSchema#string

Sharon-Lise T Normand

http://www.w3.org/2001/XMLSchema#string

Sudeep S Gill

http://www.w3.org/2001/XMLSchema#string

Walter P Wodchis

http://www.w3.org/2001/XMLSchema#string

P2860

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data.

Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review.

National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.

New evidence for stroke prevention: scientific review.

Pharmacologic therapy for behavioral symptoms of Alzheimer's disease.

Atypical antipsychotics and risk of cerebrovascular accidents.

Nose bleeds associated with use of risperidone.

Nonpharmacologic treatment of behavioral disturbance in dementia.

P304

445

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJ.38330.470486.8F

http://www.w3.org/2001/XMLSchema#string

P407

P433

7489

http://www.w3.org/2001/XMLSchema#string

P478

330

http://www.w3.org/2001/XMLSchema#string

P50

Connie Fernández-Cid Marras

P577

2005-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15668211

http://www.w3.org/2001/XMLSchema#string

P932

549652

http://www.w3.org/2001/XMLSchema#string